跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
OPSYNVI - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
OPSYNVI
Authorized
STANDARD
OPSYNVI
Janssen Inc
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
fdb20cbcfca8d167
Company
Janssen Inc
Type
Standard
Approval Details
Approval Id
fdb20cbcfca8d167
Drug Approval Canada Name
OPSYNVI
Product Name
OPSYNVI
Status
Marketed
Status Date
2021-11-25
Original Market Date
2021-11-25
Din
02521083
Drug Class
Human
Dosage Form
Tablet
Route Of Administration
Oral
Schedule
Prescription
Ahfs
48:48.12
Atc Original
C02KX54 MACITENTAN AND TADALAFIL
Atc Name
c 02 kx 54
Aig Number
0263194001
Company Name
Janssen Inc
Company Address
19 Green Belt Drive, Toronto, Ontario, Canada, M3C 1L9
Company Detail Path
/organization/janssen-inc
Company Information
Pharmaceutical Company Name
Janssen Inc
Country Name
Canada
Province Name
Ontario
City Name
north york,ontario,country_ca
Address
19 Green Belt Dr
Active Ingredients
MACITENTAN
10 MG
TADALAFIL
40 MG
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
fdb20cbcfca8d167
Type
Standard
Back to Health Canada Approvals